Copyright © 2016
Aridis Pharmaceuticals, Inc.
5941 Optical Court, San Jose, CA 95138
Board of Directors
Eric J. Patzer, Ph.D.
Chairman of the Board
Dr. Patzer, currently President of Aridis, has served as a member of Aridis’ Board of Directors since 2014. He has more than 25 years experience in biotechnology and was involved in the development of many pioneering biotechnology products at Genentech (Activase®, Protropin®, Herceptin® and Xolair®) and managed a large part of the development effort as VP Product Development. In 1996, he joined Aviron (now MedImmune Vaccines) as VP Development to build the expertise needed to advance new vaccines from research through product development. He was project leader of the intranasal influenza vaccine (FluMist™) during preclinical and clinical development. Dr. Patzer received his Ph.D. in Microbiology at the University of Virginia and was a Helen Hay Whitney Fellow at Stanford University.
Isaac Blech, B.A.
Mr. Blech is among the most successful company founders and private financiers in the biotechnology industry. Over the past 35 years, Mr. Blech established some of the most renown biotechnology companies in the world, including Celgene Corporation, ICOS Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation and Genetics Systems Corporation. Collectively, these companies have produced major advances in a broad array of diseases, including the diagnosis and treatment of cancer, chlamydia, sexual dysfunction, cystic fibrosis and AIDS, with a combined value of more than $100 billion. Mr. Blech earned a B.A. degree from Baruch College in 1975.
Vu L. Truong, Ph.D.
Chief Executive Officer and Director
Dr. Truong is a founder of Aridis and was elected CEO in 2014 after having served as the company's Chief Scientific Officer for the past nine years. He has more than 20 years experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to MedImmune) and MedImmune (sold to Astra Zeneca). Having maintained a life-
Robert Ruffolo, Ph.D.
Dr. Ruffolo was appointed to the board of directors in April 2016. He has provided management, director and consulting services since 2008 through Ruffolo Consulting, LLC. He served as the President of Research and Development and as the Corporate Senior Vice President of Wyeth Pharmaceuticals (now Pfizer) from 2002 through 2008. In these roles, he managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion. From 2000 to 2002 he served as an Executive Vice President at Wyeth, where he was responsible for Pharmaceutical Research and Development. Prior to joining Wyeth, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) where he was Senior Vice President and Director of Biological Sciences, Worldwide. Before joining SmithKline Beecham, Dr. Ruffolo spent six years at Lilly Research Laboratories where he was Chairman of the Cardiovascular Research Committee. Dr. Ruffolo served on the board of directors of Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company, from 2010 to 2013 and has served on its scientific advisory since 2008. Throughout his career, Dr. Ruffolo has played a significant role in the discovery and/or development of a number of marketed products, including Carvedilol (Coreg/Kredex/Dilatrend) for the treatment of congestive heart failure and acute myocardial infarction, Ropinerole (Requip) for the treatment of Parkinson's Disease, Dobutamine (Dobutrex) for the treatment of congestive heart failure and Eprosartan (Teveten) for the treatment of hypertension. Dr. Ruffolo has authored nearly 500 full-
Craig Gibbs, Ph.D., M.B.A.
Dr. Gibbs worked for Gilead Sciences for nearly three decades in a variety of leadership positions spanning research, corporate development and most recently, Vice President of Commercial Strategy/Commercial Planning and Operations. His broad expertise contributed to the development and commercial launch of 12 FDA approved drugs. He currently serves on the Board of Tobira Therapeutics and is an advisor to several biotechnology companies and venture capital firms. Prior to Gilead, Dr. Gibbs served as a Scientist in the Department of Protein Engineering at Genentech. Dr. Gibbs earned his doctorate in molecular biology from the University of Glasgow in Scotland and his MBA from Golden Gate University in San Francisco.
Robert K. Coughlin
Mr. Coughlin, currently President and CEO of the Massachusetts Biotechnology Council, has been appointed to Aridis’ Board of Directors since 2014. He is familiar with all areas of the Massachusetts life sciences super cluster and is a passionate advocate for life sciences research and the biotechnology community. Mr. Coughlin has spent his career in both the public and private sectors, most recently serving as Undersecretary of Economic Development within Governor Deval Patrick's administration in 2007. Prior to this position, he was elected as State Representative to the 11th Norfolk, Massachusetts district for three terms. In the legislature, both healthcare and economic development were his priorities. In addition to his extensive government and biotechnology experience, Mr. Coughlin has held senior executive positions in the environmental services, capital management and venture capital industries. He is a graduate of the Massachusetts Maritime Academy and is a Lieutenant in the United States Naval Reserve. Mr. Coughlin has also been active in the community, having served on the boards of the Massachusetts Maritime Academy and Beth Israel Deaconess Hospital. He has served as the honorary chairman of the Great Strides Cystic Fibrosis Walk since 1996.
John F. Hamilton, M.B.A.
Mr. Hamilton was elected to Aridis' Board in 2015. Previously, he served as a director and audit chair of three companies: Vermillion Inc. from 2008 to 2013, Anesiva, Inc. in 2009 and Encompass Funds from 2012 to 2015. From 1997 until his retirement in 2007, Mr. Hamilton served as Vice President and Chief Financial Officer of Depomed, Inc., a specialty pharmaceutical company. Mr. Hamilton began his career in international banking with The Philadelphia National Bank and Crocker National Bank and went on to hold senior financial positions at several biopharmaceutical companies, including Glyko, Inc., which is now BioMarin Pharmaceuticals, and Chiron Corporation, since being acquired by Novartis. He sits on the regional Board of Directors of the Association of Bioscience Financial Officers. Mr. Hamilton received his MBA from the University of Chicago and B.A. from the University of Pennsylvania.
Breakthrough Therapies for
Antibiotic Resistant Infections